Showing 1691-1700 of 3072 results for "".
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://modernaesthetics.com/news/fda-clears-fotonas-starwalker-maqx-ultra-performance-q-switched-system/2472191/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- Study Explores Improving Neck Laxity, Wrinkle Severityhttps://modernaesthetics.com/news/ma-chief-medical-editor-leads-study-to-improve-neck-laxity-wrinkle-severity/2473621/A new case study published in Cureus by Saami Khalifian, MD; Alec D. McCarthy, MD; and Steven Yoelin, MD, investigates the efficacy and safety of an injectable therapy to treat neck wrinkles and skin laxity by utilizing a combination of hyperdiluted calcium hydroxylapatite (CaHA), platelet-r
- Aesthetics Tech Forum Returns January 9-10https://modernaesthetics.com/news/aesthetics-tech-forum-returns-january-9-10/2473717/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, emeritus founding chief medical editor Steve H. Dayan, MD, FACS, and various other editorial board members and contributors will present at the 2025 Aesthetics Tech Forum, powered by Octane, on January 9-10 in Newport Beach, Cali
- Industry Vet Didier Leclercq Joins Aerolase Leadership Teamhttps://modernaesthetics.com/news/industry-vet-didier-leclercq-joins-aerolase-leadership-team/2472958/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med onc
- Galderma Launches New Collab and Consumer-Facing Rewards Apphttps://modernaesthetics.com/news/galderma-launches-new-collab-and-consumer-facing-rewards-app/2472889/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Demystified: Your Insurance Coverage During COVID-19https://modernaesthetics.com/news/demystified-your-insurance-coverage-during-covid-19/2472913/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://modernaesthetics.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to